Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
24-WEEK RESULTS OF A BLINDED PHASE IIB DOSE-RANGING STUDY OF BARICITINIB, AN ORAL JAK1/JAK2 INHIBITOR, IN COMBINATION WITH TRADITIONAL DMARDS IN PATIENTS WITH RHEUMATOID ARTHRITIS Annual Meeting of the British-Society-for-Rheumatology and British-Health-Professionals-in-Rheumatology Taylor, P., Genovese, M., Keystone, E. C., Drescher, E., Berclaz, P., Lee, C., Fidelus-Gort, R., Schlichting, D., Beattie, S., Luchi, M., Macias, W. OXFORD UNIV PRESS. 2013: 44–45
View details for Web of Science ID 000318569000138